CAS 358970-97-5|AVE 1625
Introduction：Basic information about CAS 358970-97-5|AVE 1625, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | AVE 1625 | ||
|---|---|---|---|
| CAS Number | 358970-97-5 | Molecular Weight | 497.385 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 581.7±60.0 °C at 760 mmHg |
| Molecular Formula | C23H20Cl2F2N2O2S | Melting Point | / |
| MSDS | / | Flash Point | 305.6±32.9 °C |
Names
| Name | N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide |
|---|---|
| Synonym | More Synonyms |
AVE 1625 BiologicalActivity
| Description | Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R[1]. |
|---|---|
| Related Catalog | Research Areas >>Metabolic DiseaseSignaling Pathways >>GPCR/G Protein >>Cannabinoid Receptor |
| Target | hCB1-R:25 nM (IC50) rCB1-R:10 nM (IC50) CB2:10000 nM (IC50) |
| In Vivo | AVE1625 (10 mg/kg orally once daily), combined with Olanzapine (HY-14541) attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility[2]. AVE1625 (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 (HY-15084B) or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory[3]. Animal Model: Rats[1]. Dosage: 30 mg/kg. Administration: Oral gavage, single dose. Result: Had free access to food during the preceding night (postprandial state) caused a pronounced reduction of food intake during the subsequent 10-12 h without differences intheir locomotor activity relative to that of the control group. Caused an increase in FFA and glycerol, indicating increased lipolysis from fat tissue. Immediately resulted in a pronounced increase in VCO2 and VO2, indicating increased oxidation of energetic substrates and increased TEE. Animal Model: Female Hanover Wistar rats weighing 225 ± 8.6 g[2]. Dosage: 10 mg/kg. Administration: Orally once daily. Result: Reduced their weight markedly within the first 3 days of treatment where upon animals maintained lower body weight, although they lost about 7.3 ± 1.3 g fat during the 12 days of treatment. |
| References | [1]. Andreas W Herling, et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E826-32. [2]. Michaela Liebig, et al. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring). 2010 Oct;18(10):1952-8. [3]. Mark D Black, et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl). 2011 May;215(1):149-63. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 581.7±60.0 °C at 760 mmHg |
| Molecular Formula | C23H20Cl2F2N2O2S |
| Molecular Weight | 497.385 |
| Flash Point | 305.6±32.9 °C |
| Exact Mass | 496.059052 |
| PSA | 49.00000 |
| LogP | 5.46 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.646 |
| InChIKey | IQQBRKLVEALROM-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)N(c1cc(F)cc(F)c1)C1CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1 |
| Storage condition | -20°C |
Synonyms
| AVE-1625 |
| Drinabant |
| N-{1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl}-N-(3,5-difluorophenyl)methanesulfonamide |
| Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)- |
| UNII-61S98RLL5I |
